太龍藥業(600222.SH):接受間接控股股東不超12億元財務支持
格隆匯3月23日丨太龍藥業(600222.SH)公佈,為積極推進公司在優勢產業上迅速發展,優化公司負債結構,降低資金成本,提高經營業績,公司間接控股股東高新投控擬向公司及公司控股子公司提供不超過12億元(三年內可在該額度內循環使用)的財務支持,單筆借款的年利率原則上不高於4.2%。公司於2022年3月23日召開第九屆董事會第二次會議,審議通過了《關於公司接受間接控股股東財務支持暨關聯交易的議案》,公司獨立董事就本次交易事項發表了事前認可意見及獨立意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.